Business · National
Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway
The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.
Verified Timeline
No verified timeline updates.
What is your view on “Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway”?
This is self-selected reader participation, not representative scientific polling.

